Background: Cryoglobulinaemic vasculitis (CV) is a lymphoproliferative disorder
| INTRODUCTION
Hepatitis C virus (HCV) infection is considered a systemic disease, 1, 2 frequently including lymphoproliferative disorders, mostly mixed cryoglobulinaemia (MC) and more rarely non-Hodgkin's lymphoma. [3] [4] [5] [6] 80%-90% of MC patients are HCV-positive and a percentage ranging from 40% to 60% of HCV patients show cryoglobulinaemia; within patients with cryoglobulinaemia, 5%-30% develop symptomatic MC vasculitis (CV), also called MC syndrome. 4, 5 Although CV is considered benign, it can lead to many complications, sometimes severe, which can affect the patient's quality of life. [7] [8] [9] [10] [11] Aetiological therapy is the first-line option in HCV-CV patients and, for the past 15 y, pegylated-interferon (Peg-IFN) coupled with ribavirin (RBV) has represented the standard of care. 10, [12] [13] [14] In the majority of cases, viral eradication leads to CV clinical remission. 2, [13] [14] [15] The treatment of HCV infection experienced an important advancement with the introduction of new direct-acting anti-virals (DAAs), allowing IFN-free regimens, shorter treatments and minimising side effects. [16] [17] [18] Data regarding these new IFN-free regimens for the treatment of CV patients are still limited, and based on uncontrolled studies and short follow-ups. These studies are generally consistent with high rates of symptom remission in patients with sustained virological response (SVR), as well as a high tolerance of therapy. [19] [20] [21] [22] [23] [24] [25] HCV was shown to have a tremendous impact on patientreported outcomes, such as health-related quality of life (HQoL) and fatigue. 26, 27 The value of IFN-free regimens in modifying such a negative impact can be fully appreciated by combining clinical outcomes and patient-reported outcomes. 28, 29 Some extra-hepatic conditions such as CV could greatly affect HQoL, and the effect of treatment on this aspect of the disease should be considered as an important part of the therapy outcome. 30 To our knowledge, this is the first prospective, controlled study evaluating patients with CV, patients with circulating cryoglobulins without vasculitis (MC) and patients with no evidence of MC/CV or other lymphoproliferative disorders (HCV controls), before, during and after treatment with IFN-free DAA regimens. Safety, clinical efficacy, virological response and the impact of treatment on HQoL were compared and evaluated among the 3 different groups of HCV-infected subjects.
| PATIENTS AND METHODS

| Patients
Between January 2015 and March 2016, we enrolled consecutive patients with detectable levels of serum HCV-RNA and eligibility for IFN-free anti-viral treatment, at the out-patient clinic of the Interdepartmental Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), University of Florence, Florence, Italy, according to previously described inclusion criteria. 13 The study included 3 different patient groups: Group "CV": HCV patients with cryoglobulinaemic vasculitis; Group "MC": HCV patients with circulating cryoglobulins without symptoms; Group "HCV": patients without CV, cryoglobulins or any other autoimmune/lymphoproliferative disorders. Subjects with uncertain classification were excluded from the study. 
| Treatment
Patients were treated with IFN-free DAA combinations (Table 1) according to the recommendations of the European Association for the Study of the Liver, 31 on which the Italian Association for the Study of the Liver and the Italian Medicines Agency guidelines are based, and were partly administered on compassionate use.
| Laboratory and clinical assessments
All evaluations were performed at baseline, at week 4 of treatment, at the end of treatment (EOT) and at weeks 12 and 24 of the posttherapy follow-up. Liver-related biochemical parameters (alanine aminotransferase, aspartate aminotransferase, total and direct bilirubin) were also evaluated through routine tests.
|
Liver disease stage was assessed by non-invasive methods including liver elastography using FibroScan (Echosens, Paris, France), imaging, clinical presentation and laboratory data; the METAVIR score and Child-Pugh scoring system for cirrhotic patients were used to assess the severity of liver damage.
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| MC laboratory and clinical parameters
To assess MC diagnosis, circulating cryoglobulins were determined in at least 3 metachronous samples. 32 The percentage of packed cryoglobulins in the serum, the cryocrit, was assessed following the same Clinical evaluation of CV was performed at EOT and at weeks 12 and 24 of the post-therapy follow-up in relation to previous studies 33 and to the current classification criteria. 5, [34] [35] [36] In detail, purpura was assessed as previously shown 33 Raynaud phenomenon response was evaluated considering the attack number in a 2-week period and severity according to the VAS scale (0-100), as previously suggested. 36 On this basis, we considered the disappearance of attacks as a complete response, the reduction of at least 30% frequency and severity of the attacks as an improvement and, a reduction of less than 30% as a nonresponse.
| Efficacy assessments
SVR was defined as an undetectable serum HCV-RNA at week 12 (SVR12) after therapy cessation; a HCV-RNA evaluation was performed at week 24 of the post-treatment follow-up (SVR24).
Clinical and immunological response was assessed following previously used criteria. 22, 37 Briefly, we considered "full-complete responders" patients with the disappearance of all baseline symptoms, and "complete responders" those with improvement of all the baseline symptoms, "partial responders" those with the disappearance or improvement of at least half of the baseline symptoms, and "non-responders" patients with the disappearance or improvement of fewer than half of the baseline symptoms.
MC immunological response was "complete" in the case of the disappearance of cryoglobulins, "partial" for a decrease of cryocrit to <50% of baseline level, and "null" in all other cases, following previously accepted criteria. 
| Safety assessment
Patients were monitored for the occurrence of adverse events (AEs) during regularly scheduled check-ups and additional unscheduled appointments were made to ascertain the presence and/or the severity of the AE reported by telephone.
| Statistical analysis
Quantitative variables were analysed using one-way analysis of variance (nonparametric ANOVA) or with t test for unpaired samples.
Categorical variables were analysed with the χ 2 test and Fisher's included in a previous uncontrolled study. 22 The flow chart of the 3 study groups is reported in Data S1. The main baseline demographical, clinical and virological characteristics of the study population are reported in Table 1 . The groups were homogeneous for the majority of the characteristics and parameters we evaluated, with, as expected, higher mean age and number of women in the CV population compared to the other groups (Table 1 ); in addition, the Italian criteria of DAA eligibility at the time of enrolment permitted us to treat F0-F2 patients only when clinically significant mixed cryoglobulinaemia or lymphoma was diagnosed and, therefore, some liverrelated parameters resulted as less altered in patients belonging to the CV group compared to the others (Table 1) .
DAA-based IFN-free regimens were administered combined with RBV in 20/43 (46.5%) HCV-ctrs, in 28/54 (52%) MC patients and in 59/85 (69%) CV patients.
All but 3 patients reached EOT; among the 179 patients who completed the treatment, 6 experienced a relapse by week 4 of the post-therapy follow-up.
Patients were followed up for a median of 16.4 months (range 9-23) after the completion of therapy.
As a further 7 patients were lost to follow-up after the EOT, 166 patients (41/43 HCV-ctrs; 48/54 MC; 77/85 CV) were monitored until at least week 24 after the EOT.
| Virological and hepatological response
An "intention to treat" analysis was possible on 182 patients and a "per protocol analysis" on 179 patients in regard to virological outcome.
Following the intention to treat analysis, SVR12, confirmed by Three patients interrupted treatment (Table 2) . One CV patient was hospitalised for the appearance of jaundice during therapy;
another patient, with severe CV, voluntarily interrupted treatment reporting a subjective worsening of a previous sensorimotor neuropathy not supported by 2 different neurological check-ups. The last patient interrupted therapy at week 9 when she underwent a liver transplant (Table 2) ; to note, this patient remained HCV-RNA negative after the liver transplant.
Among the 6 patients who relapsed by week 4 of the post-therapy follow-up, 1 poly-transfused patient was identified with an unrecognised mixed genotype infection (genotype 1b+2, Table 2) and responded to a second treatment tailored for genotype 2 (data not shown). All the other patients tested as negative in the test for This patient interrupted treatment at week 9 due to a liver transplant, and maintained a negative viraemia.
resistance-associated variants (NS3, NS5A or NS5B variants, depending on the drug combination).
According to previously published results, 22, 23 of the 166 patients who completed the post-therapy follow-up, the available liver function parameters showed an overall improvement (Table S1 ).
| CV clinical response
The 77 CV patients who experienced SVR24 were evaluated for clinical response at different time points of the post therapy follow-up (Figure 1 ). Among the 85 CV patients who initiated treatment, the 3 patients with grade C severity 14 had to be included in the virological failure group (2 of them interrupted therapy and 1 experienced a virological relapse, Table 2 ).
The behaviour of the main symptoms is reported in Table 3 . In accordance with previous reports, 22 we noted that while the improvement of some symptoms was rapid (ie purpura and skin ulcers), others such as fatigue, sicca syndrome and peripheral neuropathy were slow to respond ( Table 3 ).
The behaviour of eGFR in the 9 HCV-CV patients with kidney involvement who reached an SVR and completed the follow-up until SVR24 are reported in Table S2 . None of these patients had baseline eGFR levels <30 mL/min and showed a long-lasting eGFR worsening; | 445 in some cases there was a light decrease in eGFR during and after treatment, while SVR24 eGFR levels were maintained or slightly increased compared to baseline values.
During the post-therapy follow-up, no patients died or developed haematological malignancies.
| Immunological response
The mean cryocrit progressively decreased in MC patients from 
| Evaluation of HQoL
HQoL evaluation was available for 15/41 HCV-ctrs, 18/48 MC and 26/77 CV patients. The scores of the 8 items related to SF-36, stratified for each group and collected at EOT, SVR12 and SVR24, are provided in Table S3 . Considering the single items, improvement reached significance for some items solely in the CV patient group (Table S3 ).
The behaviour of the 2 summary scores PCS and MCS, calculated at the same points in time, for the 3 studied populations, is reported in Figure 2 .
At baseline, CV patients were characterised by a more consider- 
| Treatment safety
Among the 182 patients who initiated DAA therapy, AEs occurred in 99 (54.4%); stratifying for the 3 study groups, AEs were reported by 15/43 (34.9%) HCV patients, by 27/54 (50%) MC patients and by 57/ 85 (67%) CV patients. On the whole, 26/182 subjects experienced more than 1 AE. As shown in detail in Table S4 , the most frequent AE was anaemia, which was related to ribavirin administration. In the majority of cases, the decrease in haemoglobin required an intervention (Table S4) , even if a blood transfusion was not needed in any instance.
One case of hyperbilirubinaemia was the most severe AE and the only one requiring therapy interruption and hospitalisation. As previously mentioned, this patient discontinued treatment after 1 week of administration as the total bilirubin score reached 24 mg/ dL (normal range 0.2-1 mg/dL). A patient complained of worsening neuropathy and voluntarily interrupted therapy; however, as previously mentioned, electroneurography and 2 different neurological consultations did not find any evidence of such worsening.
All the other AEs, reported in Table S4 , were mild and usually well tolerated.
| DISCUSSION
To our knowledge, this is the first prospective and controlled analysis of DAA-treated patients with HCV-related cryoglobulinaemia, either symptomatic (CV) or asymptomatic (MC). As described in a study performed in the IFN-based era, 13 According to previous results and well-known demographical characteristics of mixed cryoglobulinaemia subjects, 13 CV patients were older and with a female over-representation compared to MC and HCV-ctrs groups. Conversely, the less severe degree of liver disease in CV than in patients without vasculitis observed in this study, but not in other reports, 13 was probably influenced by the Italian criteria of DAA eligibility at the time of enrolment. This allowed us to only treat patients with severe liver damage (≥F3) with the exception of patients with clinically significant mixed cryoglobulinaemia, (or lymphoma), even with mild/absent liver fibrosis. A previous controlled analysis in similar patient categories, treated with peg-IFN and RBV, showed a significant difference in the rate of SVR between HCV-ctrs and both MC and CV groups. 13 Thus, the presence of cryoglobulinaemia was a prognostic factor of non-response independent from the severity of liver disease, or other well-known prognostic factors. 13 In this study, both intention to treat and per protocol analyses confirmed the excellent virological outcome reported by previous studies on CV or MC patients treated with DAAs, 20, [22] [23] [24] [25] 40 hindering a valuable logistic regression analysis to identify outcome predictors. In other words, using DAAs, it was not possible to find significant differences in SVR rates between cryoglobulinaemic patients and controls. However, we observed that the few cases of treatment failure (patients who interrupted treatment or relapsed) generally belonged to the MC or CV groups and were advanced cases; interestingly, in one of the cases, with kidney involvement, viral relapse was followed by a consistent worsening of the cryoglobulinaemic nephropathy. This appears to be in agreement with the study by Kondo et al., where the incidence of treatment discontinuation among patients with chronic kidney disease was significantly higher than that among patients without renal damage. 41 In our study, among patients with renal involvement experiencing viral eradication, we did not observe a persistent worsening of eGFR. In Altogether, data concerning both virological and clinical/immunological response suggest that there is an opportunity to treat cryoglobulinaemic patients early preventing the evolution to severe disease forms.
The finding of more altered immunological parameters in the CV than in the MC group is consistent with previous reports 13 Our analysis partially confirmed these findings, even though we observed a higher rate of complete immunological response in CV patients. In SVR24 CV patients, the rate of complete immunological response was lower than that of complete clinical response; this discrepancy was previously reported. 13, 23, 24, 42 Longer follow-ups will be useful to assess the percentage of persistent CV stigmata. To the best of our knowledge, no previous comparative analyses on HQoL between CV vs non-CV HCV patients were available. We could show for the first time that patients with CV had lower PCS and MCS before treatment and, therefore, a worse HQoL, compared to MC and HCV-ctrs. Using a scientifically validated questionnaire, we were able to confirm our previous observations stemming from clinical practice. Even if the improvement of PCS and MCS was clear in all 3 groups, for CV patients the SVR12 and SVR24 values were significantly higher, compared to baseline scores. This means that DAA treatment could be highly beneficial for CV patients regarding HQoL, which is an important goal of therapy. These aspects, taken into account by pharmacoeconomic analyses, seem to have important implications on public expenditure, not only through direct medical costs but also through indirect costs due to decreased work productivity. This represents a relevant issue especially in countries with a high prevalence of HCV. 27, 44 Regarding therapy safety and tolerance, all the AEs were generally mild and well tolerated; however, we recorded a higher percentage of AEs in MC and CV than in HCV-ctrs. This is in accordance with a large controlled study performed on CV, MC and HCV-ctrs patients in the era of IFN-based therapy, 13 suggesting the key role played by RBV use in influencing the observed differences. The percentage of AEs in the CV group (57%) was very similar to the one reported by other authors. 13, 20, 23 In summary, our prospective/controlled analysis, including a wide population of cryoglobulinaemic patients, confirmed the high efficacy and safety of DAAs in patients with HCV-related cryoglobulinaemia.
The high SVR rates did not allow for a multivariate logistic regression analysis and no statistical differences in SVR rates were observed. However, patients who interrupted treatment or relapsed were mostly those with cryoglobulinaemia and with advanced, longlasting vasculitis. Similar correlations were observed concerning the CV clinical outcome; despite the remarkable success rate, patients with severe CV did not experience a complete response. Collectively, these data emphasise the need to identify cryoglobulinaemic patients and to treat them as soon as possible to obtain the best virological and clinical benefits. This is only feasible when a correct diagnostic approach to HCV patients has been used, so as not to underestimate the condition. 45 More interestingly, this study shows that among patients with chronic HCV infection, those with CV have significantly worse HQoL and DAA therapy is effective in increasing both physical and mental scores; this additional benefit of IFN-free treatments should be taken into account as an important goal of modern anti-viral therapy.
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